Kazia CSO Sudha Rao files initial Form 3

Kazia Therapeutics Ltd filed an initial Form 3 for Sudha Rao

Rhea-AI Filing Summary

Kazia Therapeutics Ltd filed an initial Form 3 for Sudha Rao

Key Terms

Form 3, Chief Scientific Officer, insider reporting

3 terms

Form 3 regulatory

"filed an initial Form 3 for Sudha Rao"

Form 3 is the initial public filing that officers, directors and large shareholders must submit to report their ownership of a company’s securities when they become insiders. It acts like an opening inventory sheet that gives investors a starting point to see who holds significant stakes and to spot later trades or potential conflicts of interest, helping assess insider confidence and transparency.

Chief Scientific Officer financial

"officer_title": "Chief Scientific Officer""

insider reporting regulatory

"status as an executive officer subject to insider reporting rules"

Insider reporting is the public disclosure of stock trades and holdings by a company’s executives, directors or large shareholders, filed with market regulators so investors can see when people with inside knowledge buy or sell. It matters because these actions can signal confidence or concern about a company’s future—much like a shop owner restocking or clearing shelves, insiders’ moves give clues about how those closest to the business view its prospects.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Kazia Therapeutics (KZIA) Form 3 for Sudha Rao show?

The Form 3 identifies Sudha Rao as Chief Scientific Officer of Kazia Therapeutics. It serves as her initial statement of beneficial ownership as an insider and, in this snapshot, does not list any reported transactions or derivative positions.

Who is the reporting person on the KZIA Form 3 filing?

The reporting person is Sudha Rao, who is disclosed as an officer of Kazia Therapeutics with the title Chief Scientific Officer. This confirms she is considered an insider subject to ongoing ownership and transaction reporting requirements.

Does the KZIA Form 3 for Sudha Rao report any stock purchases or sales?

No equity purchases, sales, or other insider transactions are reported for Sudha Rao in this Form 3. The transaction summary shows zero buy, sell, acquire, dispose, exercise, gift, tax withholding, or restructuring entries for this initial filing.

Are any derivative securities reported for Sudha Rao in the KZIA Form 3?

The Form 3 derivative summary is empty for Sudha Rao, indicating no listed options, warrants, or other derivative securities in this particular filing. Only her role and insider status as Chief Scientific Officer are highlighted in the disclosure.

Why is a Form 3 filed for Kazia Therapeutics officer Sudha Rao?

Form 3 is required when a person becomes an insider, such as an executive officer. For Sudha Rao, it formally starts her SEC reporting history as Chief Scientific Officer of Kazia Therapeutics, providing a baseline for any future ownership and transaction disclosures.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/19/2026 - 01:07 PM EDT Learn about SEC filing dates

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Rao Sudha

(Last) (First) (Middle)

THREE INTERNATIONAL TOWERS

LEVEL 24, 300 BARANGAROO AVE

(Street)

SYDNEY, NSW 2000

(City) (State) (Zip)

AUSTRALIA

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
04/13/2026

3. Issuer Name and Ticker or Trading Symbol
KAZIA THERAPEUTICS LTD [ KZIA ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Scientific Officer

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

Exhibit 24 - Power of Attorney

No securities are beneficially owned.

	/s/ Jeffrey Bonacorda	05/19/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)